Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mutated genes responsible for inherited cardiomyopathies represent therapeutic targets for gene replacement or augmentation strategies. These therapies aim to correct the underlying genetic defect by introducing a functional copy of the gene or enhancing expression of the existing healthy allele. Common targets include MYBPC3 in hypertrophic cardiomyopathy and RBM20 in dilated cardiomyopathy.
Gene replacement or augmentation therapy; introduction of functional gene copy or enhancement of existing expression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mutated Genes Causing Inherited Cardiomyopathies.